Item no. |
TRC-C242500-250mg |
Manufacturer |
Toronto Research Chemicals
|
CASRN |
27164-46-1 |
Amount |
250 mg |
Quantity options |
100 mg
10 g
1 g
250 mg
25 g
500 mg
|
Category |
|
Type |
Biochemicals |
Specific against |
other |
Purity |
98% |
InCHI |
1S/C14H14N8O4S3.Na/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);/q;+1/p-1/t9-,12-;/m1./s1 |
Smiles |
[Na+].Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn4cnnn4)C3=O)C(=O)[O-])s1 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
(6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt; (6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt; (6R-trans)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt; 3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt; 3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-7-[2-(1H-tetrazol-1-yl)-acetamido]-3-cephem-4-carboxylic acid sodium salt; 3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt; Acef; Ancef; Atirin; Biazolina; Bor-Cefazol; Cefacidal; Cefamedin; Cefazil; Cefazina; Cefazoliin; Cefazolin sodium; Cefazolin sodium salt; Cefazoline sodium; Cefazorin DC; Cephazolin sodium; Cephazolin sodium salt; Firmacef; Gramaxin; Kefzol; Lampocef; Liviclina; Monosodium cafazolin; NSC 291561; Reflin; SKF 41558; Sodium CEZ; Sodium cefazolin; Sodium cephazolin; Totacef; Zolicef; Sodium (6R,7R)-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
Available |
|
Mol. Weight |
476, 49 |
Country of Origin |
Canada |
IUPAC |
sodium; (6R, 7R)-3-[(5-methyl-1, 3, 4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
Storage Condition |
-20 |
Shipping Condition |
RT |
Shipping Info |
Not a Dangerous good |
Hazardous Class |
May cause allergy or asthma symptoms or breathing difficulties if inhaled |
Manufacturers Category |
Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites; Antibotics; Semi-Synthetic; |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.